To evaluate the clinical significance of PRKCQ-AS1 in tamoxifen resistance, ISH was performed on tissue microarrays from 152 tamoxifen-treated breast cancer patients in the Ruijin cohort (Fig. 1C). Here, PRKCQ is linked to breast carcinoma.